Aardvark Therapeutics, Inc. Common Stock AARD Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0— | $0— | $0— | $0— | $0— | ||
| $16.57M+15.9% | $14.3M+4.1% | $13.74M+4.5% | $13.15M+69.5% | $7.76M-3.8% | ||
| $5.9M+33.9% | $4.41M+11.1% | $3.97M+46.7% | $2.7M-0.4% | $2.72M+95.6% | ||
| $22.46M+20.1% | $18.7M+5.7% | $17.7M+11.7% | $15.85M+51.4% | $10.47M+10.8% | ||
| -$22.46M-20.1% | -$18.7M-5.7% | -$17.7M-11.7% | -$15.85M-51.4% | -$10.47M-10.8% | ||
| $876K-20.8% | $1.11M-20.3% | $1.39M-6.3% | $1.48M+27.7% | $1.16M+72.9% | ||
| -$21.59M-22.7% | -$17.6M-7.9% | -$16.32M-13.6% | -$14.37M-54.3% | -$9.31M-6.0% | ||
| -$0.99-22.2% | -$0.81-8.0% | -$0.75-13.6% | -$0.66+7.0% | -$0.71+67.4% | ||
| -$22.45M-20.1% | -$18.69M-5.7% | -$17.69M-11.7% | -$15.84M-51.3% | -$10.47M-10.8% | ||
| -$22.46M-20.1% | -$18.7M-5.7% | -$17.7M-11.7% | -$15.85M-51.4% | -$10.47M-10.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Aardvark Therapeutics, Inc. Common Stock profitable?
- Aardvark Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $69.9M over the trailing twelve months.
- What is Aardvark Therapeutics, Inc. Common Stock's earnings per share?
- Aardvark Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-3.21.
- Where does Aardvark Therapeutics, Inc. Common Stock's income statement data come from?
- Every line is extracted from Aardvark Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.